These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 10713636)

  • 1. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
    Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
    Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
    Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
    Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
    Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
    Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant.
    Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ
    Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant.
    Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A
    Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
    Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
    Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma.
    Tomblyn M; Burns LJ; Blazar B; Wagner J; Lee C; Rogers T; McGlave P; Miller JS; Weisdorf DJ
    Bone Marrow Transplant; 2007 Jul; 40(2):111-8. PubMed ID: 17530003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
    Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
    Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC).
    Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant.
    Maharaj D; Steinberg JP; Gouvea JV; Gieser PW
    Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.
    Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J
    Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.